These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Resorption is not essential for the stimulation of bone growth by hPTH-(1-34) in rats in vivo. Hock JM, Hummert JR, Boyce R, Fonseca J, Raisz LG. J Bone Miner Res; 1989 Jun; 4(3):449-58. PubMed ID: 2527459 [Abstract] [Full Text] [Related]
4. Anabolic effect of human synthetic parathyroid hormone-(1-34) depends on growth hormone. Hock JM, Fonseca J. Endocrinology; 1990 Oct; 127(4):1804-10. PubMed ID: 2401235 [Abstract] [Full Text] [Related]
11. Both hPTH(1-34) and bFGF increase trabecular bone mass in osteopenic rats but they have different effects on trabecular bone architecture. Lane NE, Yao W, Kinney JH, Modin G, Balooch M, Wronski TJ. J Bone Miner Res; 2003 Dec; 18(12):2105-15. PubMed ID: 14672345 [Abstract] [Full Text] [Related]
14. Cyclical treatment of osteopenic ovariectomized adult rats with PTH(1-34) and pamidronate. Cheng PT, Chan C, Müller K. J Bone Miner Res; 1995 Jan; 10(1):119-26. PubMed ID: 7747618 [Abstract] [Full Text] [Related]
15. The positive effect of parathyroid hormone on femoral neck bone strength in ovariectomized rats is more pronounced than that of estrogen or bisphosphonates. Søgaard CH, Wronski TJ, McOsker JE, Mosekilde L. Endocrinology; 1994 Feb; 134(2):650-7. PubMed ID: 8299562 [Abstract] [Full Text] [Related]
16. Indomethacin does not inhibit the anabolic effect of parathyroid hormone on the long bones of rats. Gera I, Hock JM, Gunness-Hey M, Fonseca J, Raisz LG. Calcif Tissue Int; 1987 Apr; 40(4):206-11. PubMed ID: 3107773 [Abstract] [Full Text] [Related]
17. Intermittent treatment with human parathyroid hormone (hPTH[1-34]) increased trabecular bone volume but not connectivity in osteopenic rats. Lane NE, Thompson JM, Strewler GJ, Kinney JH. J Bone Miner Res; 1995 Oct; 10(10):1470-7. PubMed ID: 8686502 [Abstract] [Full Text] [Related]
19. Maintaining bone mass by bisphosphonate incadronate disodium (YM175) sequential treatment after discontinuation of intermittent human parathyroid hormone (1-34) administration in ovariectomized rats. Takano Y, Tanizawa T, Mashiba T, Endo N, Nishida S, Takahashi HE. J Bone Miner Res; 1996 Feb; 11(2):169-77. PubMed ID: 8822340 [Abstract] [Full Text] [Related]